A recent phase 2a randomized, placebo-controlled trial with 50 patients evaluating brepocitinib as a therapy for LPP, FFA, and CCCA found that brepocitinib significantly reduced scalp expression of C-C motif chemokine ligand 5 (CCL5), a marker of IFNγ activity, and improved clinical severity scores, including LPPAI, Frontal Fibrosing Alopecia Severity Index (FFASI), and Central Hair Loss Grade (CHLG) across all disease subtypes by week 24, with further improvement through week 48 [48]. Here, CCL5 is linked to alopecia.